Skip to main content

OptiBiotix chief hails commercial progress

OptiBiotix chief hails commercial progress

A York business, which develops compounds to tackle obesity, high cholesterol and diabetes, has reported widening first-half losses but its chief executive has hailed a period of “significant progress” that included deals with two multinationals.

However, chief executive Stephen O’Hara praised the progress the business has made as it continues to commercialise its products.

“OptiBiotix has made significant progress in the last six months advancing our development programmes, building our IP portfolio, and signing commercial agreements with two multinationals,” he said.

See the article in full at